BSA
JAZZ icon

Braun Stacey Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Braun Stacey Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-94,289
Closed -$11.4M – 123
2024
Q1 		$11.4M Sell
94,289
-3,734
-4% -$457K 0.45% 83
2023
Q4 		$12.1M Sell
98,023
-11,901
-11% -$1.49M 0.54% 76
2023
Q3 		$14.2M Sell
109,924
-10,563
-9% -$1.41M 0.69% 67
2023
Q2 		$14.9M Sell
120,487
-118,803
-50% -$16M 0.69% 70
2023
Q1 		$35M Buy
239,290
+120,749
+102% +$17.9M 0.92% 50
2022
Q4 		$18.9M Buy
118,541
+242
+0.2% +$35.5K 1.08% 39
2022
Q3 		$15.8M Sell
118,299
-4,006
-3% -$609K 0.96% 46
2022
Q2 		$19.1M Buy
122,305
+8,942
+8% +$1.38M 1.09% 27
2022
Q1 		$17.6M Buy
113,363
+66,503
+142% +$9.65M 0.73% 68
2021
Q4 		$5.97M Buy
+46,860
New +$6.16M 0.22% 101
2016
Q1 		– Sell
-7,338
Closed -$1.03M – 154
2015
Q4 		$1.03M Sell
7,338
-73,899
-91% -$10.2M 0.06% 108
2015
Q3 		$10.8M Sell
81,237
-19,536
-19% -$3.36M 0.72% 76
2015
Q2 		$17.7M Sell
100,773
-13,284
-12% -$2.39M 0.76% 59
2015
Q1 		$19.7M Sell
114,057
-28,688
-20% -$4.92M 1.15% 22
2014
Q4 		$23.4M Sell
142,745
-11,540
-7% -$1.92M 1.42% 4
2014
Q3 		$24.8M Sell
154,285
-8,634
-5% -$1.33M 1.53% 3
2014
Q2 		$24M Sell
162,919
-32,853
-17% -$4.56M 1.42% 5
2014
Q1 		$27.1M Sell
195,772
-75,318
-28% -$11.3M 1.59% 4
2013
Q4 		$34.3M Sell
271,090
-42,120
-13% -$4.36M 1.96% 2
2013
Q3 		$28.8M Buy
313,210
+3,300
+1% +$266K 1.77% 2
2013
Q2 		$21.3M Buy
+309,910
New +$18.9M 1.34% 10

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Braun Stacey Associates's JAZZ Position: Q2 2024 in Review

Braun Stacey Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 94,289 shares — an estimated $11.4M sold.

Braun Stacey Associates first reported a position in JAZZ in Q2 2013 and held it in 21 quarters. The position peaked at $35M in Q1 2023. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Braun Stacey Associates reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Braun Stacey Associates sold 94,289 Jazz Pharmaceuticals shares in Q2 2024, an estimated $11.4M.
  • Braun Stacey Associates first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 21 quarters.
  • Braun Stacey Associates's Jazz Pharmaceuticals position peaked at $35M in Q1 2023.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Braun Stacey Associates's 13F filing for Q2 2024, filed 29 Jul 2024.